Onkologie. 2019:13(2):78-82 | DOI: 10.36290/xon.2019.015

Current clinical utility of prostate cancer markers

Štěpán Veselý
Urologická klinika 2. LF UK a FN v Motole, Praha

Significant advances in understanding of prostate cancer biology induce a rapid development of modern diagnostic tests. Several
novel biomarkers have been recently introduced. However, with regard to current tendencies in the treatment of prostate cancer
there is a need for reliable marker discriminating not only between malign and benign prostatic disease but mainly between indolent
and aggressive cancer. The following article presents an overview of both established and new promising markers of prostate cancer.
Some of novel biomarkers carry the potential to improve prostate cancer diagnostics and to enable risk stratification in clinical practice.

Keywords: prostate cancer, molecular markers, biomarkers, risk stratification

Published: April 5, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Veselý Š. Current clinical utility of prostate cancer markers. Onkologie. 2019;13(2):78-82. doi: 10.36290/xon.2019.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet 1853; 1: 393.
    2. Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. Cancer J Clin. 2016; 66: 7-30. Go to original source... Go to PubMed...
    3. Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer 2016; 138: 1388-400. Go to original source... Go to PubMed...
    4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of followup. Lancet 2014; 384: 2027-2035. Go to original source... Go to PubMed...
    5. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of followup. J Natl Cancer Inst. 2012; 104: 125-132. Go to original source... Go to PubMed...
    6. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017; 71(4): 618-629. Go to original source... Go to PubMed...
    7. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992; 267(16): 2227-8. Go to original source...
    8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <or=4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246. Go to original source... Go to PubMed...
    9. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279: 1542-7. Go to original source... Go to PubMed...
    10. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostatespecific antigen velocity and doubling timeas predictors for prostate cancer. J Clin Oncol. 2009; 27: 398-403. Go to original source... Go to PubMed...
    11. Sölétormos G, Semjonow A, Sibley PE, et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem. 2005; 51, 1342-51. Go to original source... Go to PubMed...
    12. Bhat NR, Vetter JM, Andriole GL, et al. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy. Urology 2018; 18: 1324-8.
    13. Nordström T, Akre O, Aly M, et al. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018; 21(1): 57-63. Go to original source... Go to PubMed...
    14. Le BV, Griffin CR, Loeb S, et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010; 183: 1355-59. Go to original source... Go to PubMed...
    15. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003; 52, 86-91. Go to original source... Go to PubMed...
    16. Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000; 60: 756-9.
    17. Mikolajczyk SD, Marks LS, Partin AW, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802. Go to original source... Go to PubMed...
    18. Jansen FH, van Schaik RH, Kurstjens J. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010; 57: 921-7. Go to original source... Go to PubMed...
    19. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 2011; 60: 214-22. Go to original source... Go to PubMed...
    20. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 2013; 112(3): 313-321. Go to original source... Go to PubMed...
    21. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008; 6: 19-24. Go to original source... Go to PubMed...
    22. Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol. 2015; 68(2): 207-213. Go to original source... Go to PubMed...
    23. NCCN Clinical Practice Guidelines in Oncology, 2017. Prostate Cancer Early Detection. Version 1.2018 - 14 February 2018. Dostupné z: www.nccn.org
    24. Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012; 188(5): 1726-31. Go to original source... Go to PubMed...
    25. Wei JT, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014; 32 (36): 4066-4072. Go to original source... Go to PubMed...
    26. Haese A, et al. Clinical utility of the PCA3 urine assay in European men scheduledfor repeat biopsy. Eur Urol. 2008; 54 (5): 1081-1088. Go to original source... Go to PubMed...
    27. Ploussard G, et al. Prostate cancer antigen 3 score accurately predicts tumourvolume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011; 59 (3): 422-429. Go to original source... Go to PubMed...
    28. Tomlins SA, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostatecancer risk assessment. Eur Urol. 2016; 70 (1): 45-53. Go to original source... Go to PubMed...
    29. Van Neste L, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur. Urol. 2016; 70 (5): 740-748. Go to original source... Go to PubMed...
    30. Hendriks RJ, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate 2017; 77: 1401-1407. Go to original source... Go to PubMed...
    31. McKiernan J, et al. A novel urine exosome gene expression assay to predict highgrade prostate cancer at initial biopsy. JAMA 2016; 2 (7): 882-889. Go to original source...
    32. Chan TA, et al. Convergence of mutation and epigenetic alterations identifiescommon genes in cancer that predict for poor prognosis. PLoS Med. 2008; 5(5): 114-16. Go to original source...
    33. Stewart GD, et al. Clinical utility of an epigenetic assay to detect occult prostatecancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013; 189 (3): 1110-1116. Go to original source... Go to PubMed...
    34. Partin AW, et al. Clinical validation of an epigenetic assay to predict negativehistopathological results in repeat prostate biopsies. J Urol. 2014; 192 (4): 1081-1087. Go to original source... Go to PubMed...
    35. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014; 66(3): 550-560. Go to original source... Go to PubMed...
    36. Cullen J, Rosner IL, Brand TC, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low - and intermediate-risk prostate cancer. Eur Urol. 2014; 68(1): 123-131. Go to original source... Go to PubMed...
    37. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014; 192(2): 409-414. Go to original source... Go to PubMed...
    38. Punnen S, Freedland SJ, Presti JC, Jr., et al. Multiinstitutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014; 65(6): 1171-1177. Go to original source... Go to PubMed...
    39. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013; 8(6): 115-18. Go to original source...
    40. Cooperberg MR, Davicioni E, Crisan A, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. EurUrol. 2015; 67(2): 326-333. Go to original source... Go to PubMed...
    41. Crawford ED, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014; 30(6): 1025-1031. Go to original source... Go to PubMed...
    42. Azad AA, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015; 21(10): 2315-2324. Go to original source... Go to PubMed...
    43. Romanel A, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015; 7: 312-16. Go to original source... Go to PubMed...
    44. Wyatt AW, et al. Genomic alterations in cell-free DNA and enzalutamide resistence in castration-resistant prostate cancer. JAMA Oncol. 2016; 2(12): 1598-1606. Go to original source... Go to PubMed...
    45. de Bono JS, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19): 6302-6309. Go to original source... Go to PubMed...
    46. Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patiens treated with abiraterone acetate. Eur Urol. 2011; 60(5): 897-904. Go to original source... Go to PubMed...
    47. Okegawa T, Itaya N, Hara H, et. al. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res. 2014; 34(11): 6705-6710. Go to PubMed...
    48. Antonarakis ES, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11): 1028-1038. Go to original source... Go to PubMed...
    49. Bernemann C, et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur Urol. 2017; 71(1): 1-3. Go to original source... Go to PubMed...
    50. Bastos DA, Antonarakis ES. Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther. 2016; 10: 2289-2297. Go to original source... Go to PubMed...
    51. Heidenreich A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur Urol. 2008; 54: 976-79. Go to original source... Go to PubMed...
    52. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101-5. Go to original source... Go to PubMed...
    53. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994; 152: 1850-7. Go to original source... Go to PubMed...
    54. Mir MC, Li J, Klink JC, et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014; 66(2): 204-210. Go to original source... Go to PubMed...
    55. Vesely S, Jarolim L, Schmidt M, et al. M. Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy.Scand J Urol. 2017; 51(2): 114-119. Go to original source... Go to PubMed...
    56. Sasaki T, Sugimura Y. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Na?ve Prostate Cancer Patients.J Clin Med. 2018; 7(12): 166-169. Go to original source... Go to PubMed...
    57. Pieczonka CM, Telonis D, Mouraviev V, et al. Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice. Rev Urol. 2015; 17: 203-210. Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.